A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. (2020)
Attributed to:
Clinical Psychopharmacology of Depression
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s00213-020-05654-1
PubMed Identifier: 32909076
Publication URI: http://europepmc.org/abstract/MED/32909076
Type: Journal Article/Review
Volume: 237
Parent Publication: Psychopharmacology
Issue: 12
ISSN: 0033-3158